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A bs tr ac t
Background
The standard treatment for patients with multiple myeloma who are not candidates 
for high-dose therapy is melphalan and prednisone. This phase 3 study compared 
the use of melphalan and prednisone with or without bortezomib in previously un-
treated patients with multiple myeloma who were ineligible for high-dose therapy.
Methods
We randomly assigned 682 patients to receive nine 6-week cycles of melphalan (at 
a dose of 9 mg per square meter of body-surface area) and prednisone (at a dose of 
60 mg per square meter) on days 1 to 4, either alone or with bortezomib (at a dose 
of 1.3 mg per square meter) on days 1, 4, 8, 11, 22, 25, 29, and 32 during cycles 1 to 
4 and on days 1, 8, 22, and 29 during cycles 5 to 9. The primary end point was the 
time to disease progression.
Results
The time to progression among patients receiving bortezomib plus melphalan–
prednisone (bortezomib group) was 24.0 months, as compared with 16.6 months 
among those receiving melphalan–prednisone alone (control group) (hazard ratio 
for the bortezomib group, 0.48; P<0.001). The proportions of patients with a partial 
response or better were 71% in the bortezomib group and 35% in the control group; 
complete-response rates were 30% and 4%, respectively (P<0.001). The median dura-
tion of the response was 19.9 months in the bortezomib group and 13.1 months in 
the control group. The hazard ratio for overall survival was 0.61 for the bortezomib 
group (P = 0.008). Adverse events were consistent with established profiles of toxic 
events associated with bortezomib and melphalan–prednisone. Grade 3 events oc-
curred in a higher proportion of patients in the bortezomib group than in the control 
group (53% vs. 44%, P = 0.02), but there were no significant differences in grade 4 
events (28% and 27%, respectively) or treatment-related deaths (1% and 2%).
Conclusions
Bortezomib plus melphalan–prednisone was superior to melphalan–prednisone 
alone in patients with newly diagnosed myeloma who were ineligible for high-dose 
therapy. (ClinicalTrials.gov number, NCT00111319.)
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Therapy with melphalan plus pred-nisone, which has been the standard of care for patients with newly diagnosed 
multiple myeloma for more than 40 years,1,2 is 
associated with a median survival of 29 to 37 
months.3-6 During the past decade, high-dose 
therapy with hematopoietic stem-cell transplan-
tation has become the preferred treatment for 
patients under the age of 65 years,7-9 but older pa-
tients and patients with clinically significant co-
existing illnesses usually do not tolerate this 
treatment. Since the median age at diagnosis of 
myeloma is approximately 70 years,10 more than 
half the patients with newly diagnosed myeloma 
may not be eligible for high-dose therapy. For 
these patients, improved treatment is needed. The 
proteasome inhibitor bortezomib is active in re-
lapsed or refractory myeloma.11 On the basis of 
results of a phase 3 trial,12,13 bortezomib was ap-
proved for the treatment of myeloma in patients 
who had received at least one previous therapy.
In preclinical studies, bortezomib sensitized 
melphalan-sensitive and melphalan-resistant my-
eloma cell lines to melphalan and down-regulat-
ed cellular responses to genotoxic stress.14,15 In 
combined phase 1 and 2 trials, bortezomib plus 
melphalan had encouraging activity in patients 
with relapsed or refractory myeloma.16 These 
findings led to a combined phase 1 and 2 trial 
of bortezomib–melphalan and prednisone in pa-
tients with newly diagnosed multiple myeloma 
who were 65 years of age or older.17,18 The 
complete-response rate of 32%, the median time 
to progression of 27 months, and the estimated 
38-month survival rate of 85% were improve-
ments over the results in historical control subjects 
who received only melphalan–prednisone.17,18 Our 
phase 3 trial compared bortezomib plus mel-
phalan–prednisone with melphalan–prednisone 
alone in patients with newly diagnosed myeloma 
who were ineligible for high-dose therapy.
Me thods
Patients
Patients with newly diagnosed, untreated, symp-
tomatic, measurable myeloma who were not can-
didates for high-dose therapy plus stem-cell trans-
plantation because of age (≥65 years) or coexisting 
conditions were eligible. Measurable disease was 
defined as the presence of quantifiable M protein 
in serum or urine or measurable soft-tissue or 
organ plasmacytomas. Review boards at all par-
ticipating institutions approved the study, which 
was conducted according to the provisions of the 
Declaration of Helsinki, the International Con-
ference on Harmonization, and the Guidelines 
for Good Clinical Practice. All patients provided 
written informed consent.
Study Design and Treatment
This randomized (1:1), open-label, phase 3 study 
was conducted at 151 centers in 22 countries in 
Europe, North and South America, and Asia. Pa-
tients were recruited from December 2004 to 
September 2006. They received nine 6-week cy-
cles of melphalan (at a dose of 9 mg per square 
meter of body-surface area) and prednisone (at a 
dose of 60 mg per square meter) on days 1 to 4, 
alone or in combination with bortezomib (at a 
dose of 1.3 mg per square meter), by intravenous 
bolus on days 1, 4, 8, 11, 22, 25, 29, and 32 dur-
ing cycles 1 to 4 and on days 1, 8, 22, and 29 
during cycles 5 to 9. The planned 54-week treat-
ment corresponded to the standard duration of 
melphalan–prednisone therapy. Randomization 
was stratified according to baseline levels of β2-
microglobulin (<2.5, 2.5 to 5.5, or >5.5 mg per 
liter [<212, 212 to 466, or >466 nmol per liter]), 
serum albumin (<3.5 or ≥3.5 g per deciliter), and 
region (North America, Europe, or other region). 
Treatment was discontinued on withdrawal of the 
patient’s consent, disease progression, or the oc-
currence of unacceptable toxic effects. The dose 
of melphalan or bortezomib was reduced if there 
was any prespecified hematologic toxic effect or 
grade 3 or 4 nonhematologic toxic effect; borte-
zomib-associated neuropathic pain and periph-
eral sensory neuropathy were managed with the 
use of established dose-modification guidelines.19 
Patients with myeloma-associated bone disease 
received bisphosphonates, unless such therapy 
was contraindicated.20
The primary end point was the time to dis-
ease progression. Prespecified secondary end 
points included the rate of complete response, 
the duration of response, the time to subsequent 
myeloma therapy, and overall survival. (Additional 
prespecified secondary end points are described 
in the Supplementary Appendix, available with 
the full text of this article at www.nejm.org.) The 
trial was designed by the senior academic au-
thors, in collaboration with Johnson & Johnson 
Pharmaceutical Research & Development and 
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Millennium Pharmaceuticals. Data were collected 
by the sponsors and analyzed in collaboration 
with the senior academic authors, who vouch for 
the completeness and accuracy of the data and 
the analyses. The first draft of the manuscript 
was developed by the senior academic investiga-
tors with editorial assistance from representatives 
of Johnson & Johnson Pharmaceutical Research 
& Development. Additional writing assistance 
was provided by both sponsors.
Assessments
We assessed the response to treatment using cri-
teria of the European Group for Blood and Mar-
row Transplantation (EBMT)21 and a prespecified 
computer algorithm that was validated in a previ-
ous trial.13 In a post hoc analysis, we assessed 
the response by applying an algorithm to imple-
ment the International Uniform Response Crite-
ria for Multiple Myeloma.22 Disease progression 
was determined by EBMT criteria. These criteria 
included relapse from complete response, which 
was defined as the reappearance of M protein on 
immunofixation. Investigators assessed progres-
sion on the basis of analyses of M protein in se-
rum and urine that were performed by a central 
laboratory and other factors described below. In-
vestigators provided the sponsors with documen-
tation supporting the diagnosis of progressive 
disease, which was reviewed in real time for con-
sistency with EBMT criteria.21 The sponsors also 
determined progression with the use of a comput-
er algorithm that applied EBMT criteria. Data pre-
sented here include assessments performed both 
by the investigators and by algorithmic analysis.
Blood and 24-hour urine samples were col-
lected every 3 weeks during the 54-week treat-
ment phase and then every 8 weeks until disease 
progression. Other efficacy assessments included 
bone marrow examination and skeletal survey as 
required by EBMT criteria21 or in cases in which 
such assessment was clinically required or indi-
cated on the basis of measurement of extramed-
ullary plasmacytomas or analysis of corrected 
serum calcium levels.
Patients were followed for survival and subse-
quent myeloma therapy at least every 12 weeks 
after disease progression. Safety was evaluated 
throughout the study and until 30 days after the 
administration of the last dose of a study drug. 
Adverse events were graded with the use of the 
National Cancer Institute’s Common Terminology 
Criteria for Adverse Events, version 3.0. Serious ad-
verse events were monitored monthly by the inde-
pendent data and safety monitoring committee.
Statistical Analysis
We analyzed the time to progression, the time to 
subsequent myeloma therapy, and overall survival 
from randomization and compared the differ-
ences between groups using stratified log-rank 
tests in the intention-to-treat population (all ran-
domized patients). Distributions were estimated 
with use of the Kaplan–Meier method. For time-
to-progression analyses, data from patients in 
whom there was no disease progression were cen-
sored at the last assessment or at the start of 
subsequent therapy. Hazard ratios were estimated 
with the use of the stratified Cox proportional-
hazards model for the intention-to-treat popula-
tion, as well as within subgroups that were de-
fined according to baseline characteristics in order 
to assess the consistency of treatment effects 
(seven prespecified analyses according to age, sex, 
race, baseline β2-microglobulin level, baseline albu-
min level, region, and disease stage and one post 
hoc analysis according to creatinine clearance).
Response rates were analyzed in the popula-
tion of patients who could be evaluated for a re-
sponse and were compared between groups on 
the basis of a stratified Cochran–Mantel–Haen-
szel chi-square test. The efficacy of bortezomib 
plus melphalan–prednisone was assessed post hoc 
within subgroups that were defined as having a 
poor prognosis on the basis of age (≥75 years), 
an impaired creatinine clearance (<60 ml per 
minute), or a high-risk cytogenetic profile — the 
presence of a t(4;14),t(14;16) translocation or a 
17p deletion — on the basis of fluorescence in 
situ hybridization performed at local study sites. 
Safety was analyzed in all patients who under-
went randomization and received at least one 
dose of a study drug.
Treatment differences were tested at a two-
sided alpha level of 0.05. We determined that a 
sample size of 340 patients per group would pro-
vide a power of 80% to detect a 33% improve-
ment in the time to progression in patients re-
ceiving bortezomib plus melphalan–prednisone, 
as compared with those receiving melphalan–
prednisone alone. We planned three interim 
analyses using the O’Brien–Fleming method.23 
On the basis of the third analysis (with a data 
cutoff of June 15, 2007), the data and safety 
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monitoring committee recommended that the 
study be stopped, since the prespecified statisti-
cal boundary (an alpha level of 0.0108) for the 
primary end point of time to progression had 
been crossed (hazard ratio in the bortezomib 
group, 0.54; P<0.001). Data from the third analy-
sis are presented.
R esult s
Patients and Treatment
From a total of 682 patients who were enrolled, 
we randomly assigned 344 patients to receive 
bortezomib plus melphalan–prednisone (bortez-
omib group) and 338 to receive only melphalan–
prednisone (control group) (Fig. 1 in the Supple-
mentary Appendix). Baseline demographic and 
disease characteristics were well balanced be-
tween the two groups (Table 1). Among the study 
patients, 30% were 75 years of age or older, 33% 
had a β2-microglobulin level of more than 5.5 mg 
per liter (>466 nmol per liter), and 10% reported 
having grade 1 peripheral sensory neuropathy 
before treatment. At the data cutoff point, 47 pa-
tients (14%) in the bortezomib group and 33 pa-
tients (10%) in the control group were still re-
ceiving the assigned protocol therapy.
Efficacy
The median time to progression on the basis of 
data from the central laboratory, as assessed by 
the investigators, was 24.0 months in the bortez-
omib group and 16.6 months in the control group 
(hazard ratio in the bortezomib group, 0.48; 
P<0.001) (Fig. 1A). The time-to-progression ben-
efit in the bortezomib group was independent of 
age, sex, race, baseline β2-microglobulin level, 
baseline albumin level, geographic region, clini-
cal stage (on the basis of the International Stag-
ing System24), or creatinine clearance (Fig. 2).
The response could be evaluated in 337 pa-
tients in the bortezomib group and 331 in the 
control group. The rates of partial response or 
better (according to EBMT criteria) were 71% in 
the bortezomib group as compared with 35% in 
the control group (P<0.001), and the complete-
response rates were 30% and 4%, respectively 
(P<0.001) (Table 2). In the post hoc analysis of 
response according to the International Uniform 
Response Criteria, the rates of complete response 
were 33% and 4% in the bortezomib group and 
the control group, respectively (Table 2). Of the 
79 patients in the bortezomib group who were 
considered to have stable disease on the basis 
of the International Uniform Response Criteria, 
4 had negative results on immunofixation, and 
19 had a reduction in the M protein level in se-
rum or urine of 50% or more. However, these 
patients were not recorded as having had a com-
plete or partial response, since they did not ful-
fill some aspects of the International Uniform 
Response Criteria, mainly because the confirma-
tory test results were missing. An additional 38 
patients had a reduction in M protein of 25 to 
49% or met the requirements for a minimal re-
sponse, according to EBMT criteria for nonsecre-
tory disease.
The median duration of a response (according 
to EBMT criteria) was 19.9 months in the bortez-
omib group and 13.1 months in the control 
group; the median duration of response among 
patients who had a complete response was 24.0 
months in the bortezomib group and 12.8 months 
in the control group. The median time to subse-
quent therapy and the associated treatment-free 
interval were significantly longer in the bortezo-
mib group than in the control group, with 35% 
and 57% of patients, respectively, starting second-
line treatment within 2 years (Table 2, and Fig. 2B 
in the Supplementary Appendix). Of 121 patients 
in the control group who received subsequent 
therapy, 54 (45%) received therapy that included 
bortezomib.
After a median follow-up of 16.3 months, 45 
patients (13%) in the bortezomib group and 76 
patients (22%) in the control group had died 
(hazard ratio in the bortezomib group, 0.61, 
P = 0.008); median survival was not reached in 
either group (Fig. 1B).
We also assessed the efficacy of bortezomib 
therapy in three subgroups of patients who had 
a poor prognosis. In 107 patients who were 75 
years of age or older, as compared with 237 
younger patients, the median time to progression 
was identical, the rate of complete response (ac-
cording to EBMT criteria) was slightly lower (26% 
vs. 32%, P = 0.29), and median overall survival was 
slightly shorter (P = 0.17). The 185 patients with 
impaired renal function (creatinine clearance, 
<60 ml per minute) did not differ significantly 
from the 159 patients with normal renal function 
(creatinine clearance, ≥60 ml per minute) with 
respect to the complete-response rate (28% and 
32%, respectively), the time to progression (P = 0.09), 
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or the overall rate of survival (P = 0.99). The 26 
patients with high-risk cytogenetic profiles — in-
cluding the presence of a t(4;14),t(14;16) transloca-
tion or a 17p deletion — and the 142 patients with 
standard cytogenetic profiles had the same rate 
of complete response (28%), with similar times to 
progression (P = 0.55) and overall survival (P = 0.99). 
The results remained similar with the inclusion 
of 75 patients with a 13q deletion in the high-risk 
group (data not shown). Time-to-progression and 
survival curves for these subgroups are shown in 
Figure 3 in the Supplementary Appendix.
Adverse Events
The median number of treatment cycles adminis-
tered was 8 (46 weeks) in the bortezomib group 
and 7 (39 weeks) in the control group. The me-
dian dose intensities for melphalan and predni-
sone were the same in the two groups (99% or 
more of those expected). The bortezomib group 
and the control group did not differ significantly 
with respect to rates of death during treatment 
(5% and 4%, respectively) or treatment-related 
death (1% and 2%).
Table 3 lists the most common adverse events 
Table 1. Baseline Characteristics of the Patients.*
Variable
Bortezomib Group 
(N = 344)
Control Group 
(N = 338)
Age
Median — yr 71 71 
Range — yr 57–90 48–91
Subgroup — no. (%)
<65 yr 14 (4)  9 (3)
≥75 yr 107 (31) 101 (30)
Male sex — no. (%) 175 (51) 166 (49)
Race — no. (%)†
White 304 (88) 295 (87)
Asian  33 (10)  36 (11)
Black  5 (1)  7 (2)
Other  2 (1) 0
Region — %‡
Europe 79 78
North America 9 9
Other 11 13
Karnofsky performance status ≤70 — no. (%) 122 (35) 111 (33)
Type of myeloma — %
IgG 64 62
IgA 24 26
IgD 1 1
IgM 1 1
Light chain 8 8
Biclonal 2 2
Lytic bone lesions — no./total no. (%) 224/343 (65) 222/336 (66)
Median plasma cells on bone marrow biopsy — % 40 41
International Staging System stage — %
I 19 19
II 47 47
III 35 34
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overall and grade 3 or 4 events; also listed are 
adverse events that had specific clinical relevance. 
Hematologic toxic effects were similar in the two 
groups. Peripheral sensory neuropathy was report-
ed more frequently in the bortezomib group, in-
cluding grade 1 neuropathy in 49 patients (14%), 
grade 2 in 58 patients (17%), grade 3 in 43 pa-
tients (13%), and grade 4 in 1 patient (<1%). At 
the time of data cutoff, 74% of peripheral-neurop-
athy events had either resolved (56%) or decreased 
by at least one toxicity grade (18%) within a me-
dian of 2 months. All grade 3 or 4 gastrointesti-
nal symptoms were more frequent in the bortez-
omib group than in the control group (19% vs. 
5%), as was any grade of herpes zoster (13% vs. 
4%); the incidence of herpes zoster was reduced 
to 3% in patients in the bortezomib group who 
were receiving antiviral prophylaxis. Incidences 
of grade 3 or 4 pneumonia and deep-vein throm-
bosis were low and similar in the two groups 
(Table 3).
The rate of serious adverse events in the bor-
tez omib group was higher than that in the con-
trol group (46% vs. 36%). Fifty patients (15%) in 
the bortezomib group and 47 patients (14%) in 
the control group discontinued treatment because 
of adverse events, including 37 patients (11%) and 
35 patients (10%), respectively, who had treat-
ment-related events. Bortezomib alone was dis-
continued in an additional 63 patients (19%).
Table 1. (Continued.) 
Variable
Bortezomib Group 
(N = 344)
Control Group 
(N = 338)
Serum β2-microglobulin level
Median — mg/liter 4.2 4.3 
Range — mg/liter 1.7–21.6 0.6–60.9
Subgroup — %‡
<2.5 mg/liter 12 12 
2.5–5.5 mg/liter 55 55
>5.5 mg/liter 33 33
Albumin level
Median — g/dl 3.3 3.3 
Range — g/dl 1.3–4.7 1.4–5.0
Subgroup — %‡
<3.5 g/dl 58 62
≥3.5 g/dl 42 38
Hemoglobin — g/liter
Median 104.00 106.00 
Range 64.0–159.0 73.0–165.0
Platelet count/mm3
Median 221,500 221,500 
Range 68,000–515,000 33,000–587,000
Creatinine clearance (calculated) — %
<30 ml/min 6 5
30–60 ml/min 48 50
>60 ml/min 46 46
History of cardiac condition — no. (%) 121 (35) 105 (31)
* Percentages may not total 100 because of rounding. To convert the values for serum β2-microglobulin to nanomoles 
per liter, multiply by 84.75.
† Race was self-reported.
‡ Patients were stratified on the basis of this subgroup at randomization.
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Discussion
This phase 3 study showed that the addition of 
bortezomib to melphalan–prednisone was asso-
ciated with significant improvement in outcomes 
in patients with newly diagnosed myeloma who 
were ineligible for high-dose therapy. The median 
time to progression (the primary end point) was 
7.4 months longer in the bortezomib group than 
in the control group (hazard ratio, 0.48; P<0.001). 
This benefit was seen across all subgroups of pa-
tients, as defined according to baseline demo-
graphic and disease characteristics.
There were significant improvements associ-
ated with bortezomib therapy for all prespecified 
secondary end points, including the rate of com-
plete response (according to EBMT criteria), the 
time to subsequent myeloma therapy, and overall 
survival. The response was more rapid and du-
rable in the bortezomib group than in the con-
trol group. In the bortezomib group, the median 
time to a complete response was longer than the 
median time to the first response (Table 2), sug-
gesting that prolonged treatment might improve 
the quality of the response, as was reported for 
patients with relapsed myeloma who were receiv-
ing bortezomib alone.12 The complete-response 
rate of 30% (according to EBMT criteria) that was 
associated with bortezomib was substantial in 
phase 3 trials involving patients with myeloma 
who were 65 years of age or older.25-27 Among 
patients in the bortezomib group who had a com-
plete response, the median duration of the re-
sponse was 24 months. In the bortezomib group, 
the longer time to subsequent therapy was associ-
ated with a prolonged treatment-free interval, 
which may represent an added value for patients. 
At a median follow-up of 16.3 months, 45 patients 
in the bortezomib group and 76 in the control 
group had died (hazard ratio in the bortezomib 
group, 0.61; P = 0.008), indicating a survival bene-
fit associated with bortezomib, despite the find-
ing that 45% of patients in the control group 
received subsequent therapy that included bortez-
omib after disease progression.
Superior efficacy in the treatment of myeloma 
has now been shown with bortezomib or thalid-
omide25-27 in combination with melphalan and 
prednisone. Therefore, melphalan and prednisone 
alone can no longer be considered the standard 
of care in patients who are 65 years of age or 
older. Data from a combined phase 1 and 2 trial 
have also suggested that lenalidomide plus mel-
phalan–prednisone has clear antimyeloma activi-
ty.28 It would not be appropriate to compare the 
results of our trial with phase 3 studies of tha-
lid omide because of confounding differences in 
study populations (e.g., age), the duration of ther-
apy, the use of maintenance therapy, and especial-
ly the methodology and criteria used for defini-
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Figure 1. Kaplan–Meier Curves for the Time to Disease Progression and Overall 
Survival (Intention-to-Treat Population).
Panel A shows the time to disease progression on the basis of assessment 
by the investigators; the median time to progression was 24.0 months in 
the bortezomib group and 16.6 months in the control group (hazard ratio 
in the bortezomib group, 0.48). According to algorithmic analysis, the me-
dian time to progression was 20.7 months in the bortezomib group and 
15.0 months in the control group (hazard ratio in the bortezomib group, 
0.54; P<0.001). Panel B shows overall survival after a median follow-up of 
16.3 months. Median survival was not reached in either group. During that 
time, 45 patients (13%) in the bortezomib group and 76 patients (22%) in 
the control group died (hazard ratio in the bortezomib group, 0.61).
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tions of response and progression.29,30 Our 
study included assessment every 3 weeks, mea-
surement of the time to events starting at ran-
domization, and the use of EBMT criteria. The 
effect of methodologic differences is apparent 
within the bortezomib group: the median time 
to progression as assessed by investigators (24.0 
months) was 3 months longer than that as as-
sessed by algorithmic analysis and was not 
reached at 27 months in a post hoc analysis on 
the basis of a previously described modification 
of the International Uniform Response Criteria.25
The adverse events reported in the bortezomib 
group were consistent with established toxicity 
profiles for both bortezomib11,13,31 and melpha-
lan–prednisone.4,6 The rate of death during treat-
ment was low in both groups, as compared with 
historical data on early mortality among elderly 
patients.32,33 The rate of peripheral sensory neu-
ropathy in the bortezomib group was consistent 
with the rate reported in previous studies, taking 
into account the duration of therapy and the cu-
mulative dose of bortezomib.17,34 After only 16.3 
months of follow-up, peripheral neuropathy im-
proved or resolved in most patients, confirming 
that prompt modification of the bortezomib dose 
according to established guidelines19 is important 
to avoid severe neurotoxicity and ensure revers-
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Figure 2. Subgroup Analyses of Time to Disease Progression as Assessed by the Investigators.
The prespecified and post hoc analyses of the time to disease progression among subgroups of patients, as defined 
according to baseline demographic and disease characteristics, showed hazard ratios that were lower than 1 (indi-
cating a lower risk of progression) in the bortezomib group, as compared with the control group, for each subgroup. 
The I bars represent 95% confidence intervals. ISS denotes International Staging System. To convert the values for 
serum β2-microglobulin to nanomoles per liter, multiply by 84.75.
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Table 2. Best Response to Treatment and Time-to-Event Data.*
Response and Time to Event
Bortezomib Group 
(N = 337)
Control Group 
(N = 331) P Value†
Best response
EBMT criteria — no. (%)
Complete or partial response 238 (71) 115 (35) <0.001
Complete response 102 (30) 12 (4) <0.001
Partial response 136 (40) 103 (31) ND
Minimal response 32 (9)  72 (22) ND
Stable disease  60 (18) 133 (40) ND
Progressive disease  3 (1)  7 (2) ND
International Uniform Response Criteria — no (%)‡
Complete, very good partial, or partial response 251 (74) 128 (39) <0.001
Complete response 111 (33) 13 (4) <0.001
Very good partial response 28 (8) 13 (4) ND
Partial response 112 (33) 102 (31) ND
Stable disease  79 (23) 192 (58) ND
Progressive disease  3 (1)  7 (2) ND
Time to event
Median time to response — mo§
First response 1.4 4.2 <0.001
Complete response 4.2 5.3 <0.001
Median duration of response — mo§
Complete or partial response 19.9 13.1 ND
Complete response 24.0 12.8 ND
Time to subsequent myeloma therapy — mo¶ Not reached 20.8 <0.001
Treatment-free interval — mo¶ Not reached 9.4 ND
* A total of 14 patients, 7 in each study group, could not be evaluated for a response: 5 did not receive a study drug, and 
9 had no measurable disease at baseline on the basis of an assessment by a central laboratory, even though these pa-
tients met the eligibility criterion of measurable disease according to evaluation by a local laboratory. Among the pa-
tients who could be evaluated, responses were not determined for 4 patients in the bortezomib group and 4 in the con-
trol group. Percentages may not total 100 because of rounding. EBMT denotes European Group for Blood and Marrow 
Transplantation, and ND not determined.
† P values were calculated by stratified Cochran–Mantel–Haenszel chi-square tests for comparisons of response rates 
and by stratified log-rank tests for comparisons of time-to-event data. P values for comparisons of time to response are 
based on the total study population.
‡ Of the 79 patients in the bortezomib group who were considered to have stable disease on the basis of International 
Uniform Response Criteria and who could be evaluated, 4 patients (1%) had negative results on immunofixation (com-
plete response) and 19 (6%) had a reduction of at least 50% in the M protein level (partial response); these patients 
were not recorded as having a complete or partial response, primarily because the confirmatory test results were miss-
ing. With the inclusion of these patients, the response rate would be 81% and the complete-response rate would be 
34%. Patients could not be assessed for the category of stringent complete response because immunohistochemical, 
immunofluorescence, and free light-chain assays were not performed. The response definitions are the same as for the 
EBMT criteria, except the International Uniform Response Criteria do not require that the changes in M protein be con-
firmed a minimum of 6 weeks after the initial assessment.
§ Data were determined by computer algorithm, applying EBMT criteria.
¶ Data were based on 344 patients in the bortezomib group and 338 in the control group.
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Table 3. Adverse Events (Safety Population).*
Events
Bortezomib Group
(N = 340)
Control Group
(N = 337)
Total Grade 3 Grade 4 Total Grade 3 Grade 4
number of patients (percent)
Any event 338 (99) 181 (53) 96 (28) 326 (97) 148 (44) 92 (27)
Hematologic events† 
Thrombocytopenia 178 (52) 68 (20) 58 (17) 159 (47) 55 (16) 47 (14)
Neutropenia 165 (49) 102 (30) 34 (10) 155 (46) 79 (23) 49 (15)
Anemia 147 (43) 53 (16) 9 (3) 187 (55) 66 (20) 26 (8)
Leukopenia 113 (33) 67 (20) 10 (3) 100 (30) 55 (16) 13 (4)
Lymphopenia 83 (24) 49 (14) 18 (5) 58 (17) 30 (9) 7 (2)
Gastrointestinal events
Nausea 164 (48) 14 (4) 0 94 (28) 1 (<1) 0
Diarrhea 157 (46) 23 (7) 2 (1) 58 (17) 2 (1) 0
Constipation 125 (37) 2 (1) 0 54 (16) 0 0
Vomiting 112 (33) 14 (4) 0 55 (16) 2 (1) 0
Infections
Pneumonia 56 (16) 16 (5) 6 (2) 36 (11) 13 (4) 4 (1)
Herpes zoster 45 (13) 11 (3) 0 14 (4) 6 (2) 0
Nervous system disorders
Peripheral sensory neuropathy 151 (44) 43 (13) 1 (<1) 16 (5) 0 0
Neuralgia 121 (36) 28 (8) 2 (1) 5 (1) 1 (<1) 0
Dizziness 56 (16) 7 (2) 0 37 (11) 1 (<1) 0
Other conditions
Pyrexia 99 (29) 8 (2) 2 (1) 64 (19) 6 (2) 2 (1)
Fatigue 98 (29) 23 (7) 2 (1) 86 (26) 7 (2) 0
Anorexia 77 (23) 9 (3) 1 (<1) 34 (10) 4 (1) 0
Asthenia 73 (21) 20 (6) 1 (<1) 60 (18) 9 (3) 0
Cough 71 (21) 0 0 45 (13) 2 (1) 0
Insomnia 69 (20) 1 (<1) 0 43 (13) 0 0
Peripheral edema 68 (20) 2 (1) 0 34 (10) 0 0
Rash 66 (19) 2 (1) 0 24 (7) 1 (<1) 0
Back pain 58 (17) 9 (3) 1 (<1) 62 (18) 11 (3) 1 (<1)
Dyspnea 50 (15) 11 (3) 2 (1) 44 (13) 5 (1) 3 (1)
Hypokalemia 44 (13) 19 (6) 3 (1) 25 (7) 8 (2) 2 (1)
Arthralgia 36 (11) 4 (1) 0 50 (15) 2 (1) 1 (<1)
Deep-vein thrombosis  4 (1) 3 (1) 0 6 (2) 2 (1) 0
* Listed adverse events were reported in at least 15% of patients, and grade 3 or 4 events were reported in at least 5% of 
patients. Other adverse events of particular clinical relevance are also listed. Patients could have more than one ad-
verse event. Included are all patients who received at least one dose of a study drug.
† Rates of red-cell transfusions were 26% in the bortezomib group and 35% in the control group; rates of use of erythro-
poiesis-stimulating agents for treatment-related anemia were 30% and 39%, respectively.
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ibility. Hematologic toxic effects were similar in 
the two groups, and the incidence of deep-vein 
thrombosis was very low in both groups, even 
though the protocol did not require prophylaxis.
In conclusion, this study showed that bortez-
omib plus melphalan–prednisone was superior 
to melphalan–prednisone alone for the treat-
ment of patients with newly diagnosed myeloma 
who were ineligible for high-dose therapy, al-
though bortezomib was associated with a slight-
ly higher rate of adverse events. Our findings 
suggest that bortezomib plus melphalan–predni-
sone is a valuable front-line treatment for patients 
with myeloma who are 65 years of age or older 
and cannot receive more aggressive treatment.35
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